Aura Biosciences — Third Quarter 2026 Earnings Summary

Aura Biosciences reported a net loss of $32.1 million for the third quarter ended September 30, 2026, driven by increased research and development expenses and restructuring charges. The company's Phase 3 CoMpass trial for bel-sar in early choroidal melanoma has completed enrollment of 108 participants, with all treatment visits finished and topline data expected in the second half of 2027. Aura established a new manufacturing partnership with an industry-leading CDMO to secure designated production capacity for bel-sar. As of September 30, 2026, the company held $297.2 million in cash and marketable securities, providing a runway into the first half of 2029.